AlterM.J. (1997). Epidemiology of hepatitis C. Hepatology, 26(6):2S-5S.
2.
AnnoB.J., FaiverK.L., & HarnessJ.K. (1996). A preliminary model for determining limits for correctional health care services. Journal of Correctional Health Care, 3(1):67-84.
3.
Centers for Disease Control and Prevention (1998). Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Morbidity Mortality Weekly Report, 47(RR-19).
4.
Department of Health and Human Services, National Center for Health Statistics (NCHS). NHANES III (National Health and Nutrition Examination Survey, 1988-1994).,
5.
MarcellinP., BoyerN., GervaisA., MartinotM., PouteauM., CastelnauC., KilaniA., AreiasJ., AuperinA., BenhamouJ.P., DegottC., & ErlingerS. (1997). Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alfa therapy. Annals Int Med, 127. 875.
6.
McHutchisonJ.G., GordonS.C., SchiffE.R., ShiffmanM.L., LeeW.M., RustgiV.K., GoodmanZ.D., LingM.H., CortS., & AlbrechtJ.K. (1998). Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. New England Journal of Medicine, 339:1493-9.
7.
National Institutes of Health. (1997). Consensus development conference panel statement: Management of hepatitis C. Hepatology, 26(Suppl 1:2S-10S).
8.
RuizJ.D., MikandaJ. (1996). Seroprevalence of HIV, hepatitis B, hepatitis C, and risk behaviors among inmates entering the California correctional system. Sacramento, California: Department of Health Services.
9.
SpauldingA., GreeneC., DavidsonK., SchneidermannM., & RichJ. (1999). Hepatitis C in state correctional facilities. Preventive Medicine, 28: 92-100.
10.
Wong J.B., BennettW.G., KoffR.S.,& PaukerS.G. (1998) . Pretreatment evaluation of chronic hepatitis C: Risks, benefits and costs. Journal of the American Medical Association, 280(4):2088-93.